Everything on Pharmaceuticals & Healthcare

Novo Nordisk secured a first-mover advantage in oral weight-loss pills, capturing significantly higher prescriptions than Eli Lilly's newly approved competitor, driving notable stock divergence.

Impact: Tracking regulatory approvals and prescription uptake rates in the GLP-1 sector will help identify first-mover advantages and potential market share shifts.

— from Market Shifts: AI Compute, Intel Turnaround, and Emerging Markets · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Apr 27, 2026